$0.91
0.66% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US75120L1008
Symbol
RLYB

Rallybio Corp Stock price

$0.91
-0.19 16.92% 1M
-0.57 38.25% 6M
-1.48 61.76% YTD
-1.69 64.85% 1Y
-9.63 91.33% 3Y
-13.19 93.52% 5Y
-13.19 93.52% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 0.66%
ISIN
US75120L1008
Symbol
RLYB
Sector
Industry

Key metrics

Market capitalization $37.92m
Enterprise Value $-36.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.72
EV/Sales (TTM) EV/Sales -61.65
P/S ratio (TTM) P/S ratio 63.20
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $600.00k
EBIT (operating result TTM) EBIT $-70.00m
Free Cash Flow (TTM) Free Cash Flow $-51.08m
Cash position $75.14m
EPS (TTM) EPS $-1.59
P/E forward negative
P/S forward 56.28
EV/Sales forward negative
Short interest 1.20%
Show more

Is Rallybio Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Rallybio Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Rallybio Corp forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Rallybio Corp forecast:

Buy
100%

Financial data from Rallybio Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.60 0.60
-
100%
- Direct Costs 0.14 0.14
7% 7%
23%
0.46 0.46
407% 407%
77%
- Selling and Administrative Expenses 20 20
23% 23%
3,403%
- Research and Development Expense 50 50
3% 3%
8,318%
-70 -70
7% 7%
-11,643%
- Depreciation and Amortization 0.14 0.14
7% 7%
23%
EBIT (Operating Income) EBIT -70 -70
7% 7%
-11,667%
Net Profit -67 -67
5% 5%
-11,162%

In millions USD.

Don't miss a Thing! We will send you all news about Rallybio Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rallybio Corp Stock News

Neutral
Business Wire
19 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH...
Neutral
Business Wire
27 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116, the Company's innovative, o...
Neutral
Business Wire
about one month ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal ...
More Rallybio Corp News

Company Profile

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focuses in the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Head office United States
CEO Stephen Uden
Employees 43
Founded 2018
Website www.rallybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today